A potential usage of probiotics in prevention and treatment of neutropenic enterocolitis

• Authors: Jakub Krzysztof Gałązka , Piotr Homa , Łukasz Domagalski

Abstracts

EN

Introduction and aim. Neutropenic enterocolitis is a severe disease that affects patients with immunodeficiency and is often related with the chemotherapy of the hematologic malignancies. Its pathophysiology is not fully understood. Neutropenic colitis may lead to sepsis, gastrointestinal bleeding and even perforations requiring surgical management. The therapy consists of antibiotic therapy, transfusions, hematopoietic growth factor treatment, usage of fluids and electrolytes, bowel rest and even surgical operations. The aim of this review is to consider the potential usage of probiotics in the prevention and treatment of neutropenic enterocolitis. Material and methods. References for that article were found through PubMed and Google Scholar, using terms: “neutropenic enterocolitis” and “probiotics”, or “gut microbiota” and “neutropenic enterocolitis”. The research was limited to abstracts and available full-text articles. Analysis of the literature. The most possible mechanism of neutropenic enterocolitis development appoints bacterial invasion with co-existing immunodeficiency. The probiotics appeal as beneficial agents in both prevention and treatment of neutropenic enterocolitis in according to their impact on gut immune barrier improvement. However older societies’ guidelines were cautious, the most modern ones appoint probiotics as a promising agent in neutropenic enterocolitis, what corresponds with results from current randomized clinical trials. Conclusion. As neutropenic enterocolitis is a severe disease we need to look for better or alternative therapies of that state. The probiotics seems to have beneficial effects in terms of prevention and treatment of neutropenic enterocolitis due to their impact on gut immune barrier. Benefits of such therapy are reflected in current societies’ guidelines which consider probiotics as a promising agent in neutropenic enterocolitis.

Keywords

EN

oncology; neutropenic enterocolitis; probiotics

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2023
• Issue: 1
• Pages: 129-132

Dates

published

2023

Contributors

author

Jakub Krzysztof Gałązka

• Students’ Scientific Association at the Department and Clinic of Gastroenterology with Endoscopy Unit, Medical University of Lublin, Lublin, Poland

• https://orcid.org/000000033128773X

author

Piotr Homa

• Students’ Scientific Association at the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, Lublin, Poland

• https://orcid.org/0000000307517400

author

Łukasz Domagalski

• Students’ Scientific Association at Department and Clinic of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Lublin, Poland

• https://orcid.org/0000000169104607

References

• Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. World J Gastroenterol. 2017;23(1):42. doi: 10.3748/WJG.V23.I1.42.
• Vohra R, Prescott RJ, Banerjee SS, Wilkinson PM, Schofield PF. Management of neutropenic colitis. Surg Oncol. 1992;1(1):11-15. doi: 10.1016/0960-7404(92)90051-L.
• Cherri S, Prochilo T, Rota L, et al. Neutropenic Enterocolitis in the Treatment of Solid Tumors: A Case Report and Review of the Literature. Case Rep Oncol. 2020;13(1):442448. doi: 10.1159/000506896.
• Ettinghausen SE. Collagenous Colitis, Eosinophilic Colitis, and Neutropenic Colitis. Surgical Clinics of North America. 1993;73(5):993-1016. doi: 10.1016/S0039-6109(16)46137-2.
• Rodrigues FG, Dasilva G, Wexner SD. Neutropenic enterocolitis. World J Gastroenterol. 2017;23(1):42-47. doi: 10.3748/wjg.v23.i1.42.
• Kapandji N, Azoulay E, Zafrani L. Recent advances in neutropenic enterocolitis: Insights into the role of gut microbiota. Blood Rev. 2022;54:100944. doi: 10.1016/J. BLRE.2022.100944.
• Duceau B, Picard M, Pirracchio R, et al. Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease. Crit Care Med. 2019;47(5):668-676. doi: 10.1097/ CCM.0000000000003687.
• Bertozzi G, Maiese A, Passaro G, et al. Neutropenic Enterocolitis and Sepsis: Towards the Definition of a Pathologic Profile. Medicina (B Aires). 2021;57(6). doi: 10.3390/ MEDICINA57060638.
• Sachak T, Arnold MA, Naini B V, et al. Neutropenic enterocolitis. American Journal of Surgical Pathology. 2015;39(12):16351642. doi: 10.1097/PAS.0000000000000517.
• Saillard C, Zafrani L, Darmon M, et al. The prognostic impact of abdominal surgery in cancer patients with neutropenic enterocolitis: A systematic review and meta-analysis, on behalf the groupe de recherche en réanimation respiratoire du patient d’onco-hématologie (GRRR-OH). Ann Intensive Care. 2018;8(1):1-14. doi: 10.1186/S13613018-0394-6/FIGURES/6.
• Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol. 2022;12. doi: 10.3389/ FCIMB.2022.1042070.
• Tan F, Deng Y, Guo J, Zhou Z, Luo H. Effect of mesalazine combined with probiotics on inflammation and immune function of patients with inflammatory bowel disease. Am J Transl Res. 2022;14(11):8234-8242.
• Hu Y, Chen Z, Xu C, Kan S, Chen D. Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease. Nutrients. 2022;14(23):5140. doi: 10.3390/NU14235140.
• Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2008;(3). doi: 10.1002/14651858.CD006634.PUB2.
• Ervin SM, Ramanan SV, Bhatt AP. Relationship Between the Gut Microbiome and Systemic Chemotherapy. Dig Dis Sci. 2020;65(3):874-884. doi: 10.1007/S10620-020-061193/FIGURES/2.
• Murthy HS, Gharaibeh RZ, Al-Mansour Z, et al. Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2020;26(11):2001-2010. doi: 10.1016/J.BBMT.2020.07.023.
• Sahoo D, Seth R, Chaudhry R, et al. Outcome and Determinants of Neutropenic Enterocolitis in Pediatric Cancer Patients. J Pediatr Hematol Oncol. 2022;44(7):376-382. doi: 10.1097/MPH.0000000000002422. 132 European Journal of Clinical and Experimental Medicine 2023; 21 (1): 129–132
• Reyna-Figueroa J, Garcia-Beristain JC, Galindo-Delgado P, Limon-Rojas AE, Madrid-Marina V. Antibiotic use before chemotherapy: A risk factor for developing neutropenic colitis in children with Leukemia. J Pediatr Hematol Oncol. 2015;37(2):121-127. doi: 10.1097/ MPH.0000000000000227.
• Hassan H, Kinsey S, Phillips B. Mucositis reduction with probiotics in children with cancer: a randomised-controlled feasibility study. Arch Dis Child. 2022;107(3):259264. doi: 10.1136/ARCHDISCHILD-2020-319968.
• Arends J. How to feed patients with gastrointestinal mucositis. Curr Opin Support Palliat Care. 2018;12(2):168-173. doi: 10.1097/SPC.0000000000000345.
• Reyna-Figueroa J, Bejarano-Juvera AA, García-Parra C, Barrón-Calvillo EE, Queipo-Garcia GE, Galindo-Delgado P. Decrease of Postchemotherapy Complications With the Use of Probiotics in Children With Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2021;43(4):e457-e461. doi: 10.1097/MPH.0000000000001956.
• Österlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028-1034. doi: 10.1038/SJ.BJC.6603990.
• Linn YH, Thu KK, Win NHH. Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study. Probiotics Antimicrob Proteins. 2019;11(2):638-647. doi: 10.1007/S12602-018-9408-9.
• Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):131. doi: 10.1186/S12876019-1047-4.
• Bajramagic S, Hodzic E, Mulabdic A, Holjan S, Smajlovic SV, Rovcanin A. Usage of Probiotics and its Clinical Significance at Surgically Treated Patients Sufferig from Colorectal Carcinoma. Med Arch. 2019;73(5):316-320. doi:10.5455/MEDARH.2019.73.316-320
• Mego M, Koncekova R, Mikuskova E, et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer. 2006;14(3):285-290. doi: 10.1007/S00520-0050891-7.
• Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer. 2010;18(6):751-759. doi: 10.1007/S00520009-0711-6.
• Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018;29:iv126-iv142. doi:10.1093/annonc/mdy145
• Schmidt-Hieber M, Bierwirth J, Buchheidt D, et al. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology. 2017;97(1):3149. doi: 10.1007/S00277-017-3183-7.
• Szajewska H, Canani RB, Domellöf M, et al. Probiotics for the management of pediatric gastrointestinal disorders: position paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr:10.1097/MPG.0000000000003633. Accessed October 11, 2022. doi: 10.1097/MPG.0000000000003633.

Identifiers

DOI

10.15584/ejcem.2023.1.16

Biblioteka Nauki

2211811